

雲嘉南區消化系聯合研討會

日期：2017 年 12 月 23 日(六) 14:00-17:40

地點：大林慈濟醫院 大愛樓第一會議室

認定積分：內科醫學會、消化系醫學會及消化系內視鏡醫學會學分—
積分申請中

Time	Topic	Speaker	Moderator
13:30-14:00	Registration		
14:00-14:10	Opening		曾國枝 部長 大林慈濟醫院
14:10-14:40	Clinical application of ultrasound elastography in chronic liver disease	王景弘 教授 高雄長庚醫院	盧勝男 副院長 嘉義長庚醫院
14:40-15:10	Immune checkpoint inhibitor - Panacea for HCC ?	陳健弘 部長 雲林台大醫院	羅清池 部長 聖馬爾定醫院
15:10-15:40	ERCP 健保給付面面觀	魏國良 主任 嘉義長庚醫院	陳炯瑜 主任 成大醫院
15:40-16:00	Break		
16:00-16:30	Emerging problem in the real world DAA treatment: the blind spots of genotypes interpretation	劉振驊 教授 台大醫院	陳志州 副院長 柳營奇美醫院
16:30-17:10	Case sharing	斗六成大 沈明哲診所 嘉基 柳營奇美	徐士哲 主任/雲林台大醫院 洪肇宏 主任/嘉義長庚醫院
17:10-17:30	Discussion		陳啟益 主任 嘉義基督教醫院
17:30-17:40	Closing		吳正雄 理事長 嘉義長庚醫院

主辦單位：大林慈濟醫院 腸胃肝膽科

雲嘉南區消化系聯合研討會


課程摘要

本次雲嘉南區消化系聯合討論會邀請四位國內教授演講，討論目前肝膽腸胃科討論的問題。王景弘教授講”Clinical application of ultrasound elastography in chronic liver disease”，呼應健保目前 C 肝口服藥僅給付 F3, F4 的情形；陳健弘部長講”Immune checkpoint inhibitor - Panacea for HCC ?” 著重剛拿到 FDA approval 新藥在肝癌的使用；魏國良主任講”ERCP 健保給付面面觀”，探討目前健保在 ERCP 給付的種種問題；劉振驊教授講”Emerging problem in the real world DAA treatment: the blind spots of genotypes interpretation”，探討目前 genotypes 檢測的誤差與盲點。第二段邀請四家醫院分享精彩個案；藉由這樣的討論，讓雲嘉南地區的同好能提升各院病患的照護品質。

講師個人履歷資料

高雄長庚醫院 王景弘 教授

中文姓名	王景弘	英文姓名	Jing-Houng Wang,
國籍	台灣	性別	<input checked="" type="checkbox"/> 男 <input type="checkbox"/> 女
主要學歷	高雄醫學院醫學系		
專長	肝癌局部治療、介入性超音波、肝炎診斷及治療		
現職	高雄長庚紀念醫院胃腸肝膽科系教授級主治醫師 長庚大學兼任教授 高雄市肝病防治協會 第三屆理事長 台灣腫瘤消融醫學會 第三屆理事		
經歷	高雄醫學院附設醫院內科住院醫師 高雄醫學院附設醫院保健科及肝膽內科主治醫師 嘉義華濟醫院肝膽內科主任 高雄長庚醫院肝臟科主任 台灣肝癌醫學會第三屆監事 中華民國醫用超音波學會第十二屆監事		
論文著作	<p>Yen YH, Chang KC, Tsai MC, Tseng PL, Lin MT, Wu CK, Lin JT, Hu TH, Wang JH, Chen CH. Elevated body mass index is a risk factor associated with possible liver cirrhosis across different etiologies of chronic liver disease. J Formos Med Assoc, 2017 Sep 22.</p> <p>Huang CM, Chang KC, Hung CH, Chiu KW, Lu SN, Wang JH, Chen CH, Kee KM, Kuo YH, Tsai MC, Tseng PL, Lin MT, Wu CK, Hu TH, Cho CL, Yen YH. Impact of PNPLA3 and IFNL3 polymorphisms on hepatic steatosis in Asian patients with chronic hepatitis C. PLoS One, 2017,12(8):e0182204.</p> <p>Hung CH, Kee KM, Chen CH, Tseng PL, Tsai MC, Chen CH, Wang JH, Chang KC, Kuo YH, Yen YH, Hu TH, Lu SN. A Randomized Controlled Trial of Glycyrrhizin Plus Tenofovir vs. Tenofovir in Chronic Hepatitis B with Severe Acute Exacerbation. Clin Transl Gastroenterol,2017,8(6):e104.</p> <p>Kuo YH, Wu IP, Wang JH, Hung CH, Rau KM, Chen CH, Kee KM, Hu TH, Lu SN*. The outcome of sorafenib monotherapy on hepatocellular carcinoma with portal vein tumor thrombosis. Invest New Drugs, 2017 May 2.</p> <p>Espinosa W, Liu YW, Wang CC, Lin CC, Wang JH, Lu SN, Hung CH. Combined resection and radiofrequency ablation versus transarterial embolization for intermediate-stage hepatocellular carcinoma: A propensity score matching study. J Formos Med Assoc, 2017 Apr 13.</p> <p>Wang JH, Yen YH, Yao CC, Hung CH, Chen CH, Hu TH, Lee CM, Lu SN*. Liver stiffness-based score in hepatoma risk assessment for chronic hepatitis C patients after successful antiviral therapy. Liver Int, 2016, 36(12):1793-1799.</p> <p>Wang JH, Chen TY, Ou HY, Wang CC, Liu YW, Hung CH, Chen CH, Kuo CH, Hu TH, Cheng YF, Lu SN*. Clinical Impact of Gadoteric Acid-Enhanced Magnetic Resonance Imaging on Hepatoma Management: A Prospective Study. Dig Dis Sci,2016,61(4):1197-205.</p> <p>Wang JH, Kee KM, Lin CY, Hung CH, Chen CH, Lee CM, Lu SN*. Validation and modification of a proposed substaging system for patients with intermediate hepatocellular carcinoma. J Gastroenterol Hepatol,2015,30(2):358-63.</p>		

中文姓名	陳健弘	英文姓名	Chien-Hung Chen	
國籍	台灣	性別	<input checked="" type="checkbox"/> 男 <input type="checkbox"/> 女	
主要學歷	國立台灣大學醫學院醫學系學士 國立台灣大學醫學院臨床醫學研究所博士			
專長	臨床醫學、肝臟及消化醫學、腹部超音波學、內視鏡醫學、腫瘤免疫學及分子生物學			
現職	國立台灣大學附設醫院內科部主任 國立台灣大學附設醫院內科部主治醫師 國立台灣大學醫學院內科副教授			
經歷	台大醫院內科部住院醫師 台大醫院內科部總住院醫師 台大醫院內科部消化系研究員 國立台灣大學醫學院內科兼任講師 國立台灣大學醫學院內科臨床講師 美國約翰霍普金斯大學腫瘤部研究員 國立台灣大學附設醫院內科部主治醫師 國立台灣大學醫學院內科臨床助理教授			
論文著作	<p>Johns Hopkins Cancer Center 1999 Fellow Research Day Poster Session, Honorable Mention, Translational Research Award.</p> <p>USCAP Binford-Dammin Poster Prize Award, 1999 (from Binford-Dammin society of International Academy of Pathology)</p> <p>Cheng CP, Chen CH, Kuo CS, Kuo HT, Huang KT, Shen YL, Chang CH, Huang RFS. Dietary choline and folate relationships with serum hepatic inflammatory injury markers in Taiwanese adults. <i>Asia Pac J Clin Nutr.</i> 2017;26(4):642-649.</p> <p>Shun SC, Lai YH, Hung H, Chen CH, Liang JD, Chou YJ. The Role of Age in Change in Unmet Supportive Care Needs in Hepatocellular Carcinoma Patients During Transition From Hospital to Home. <i>Cancer Nurs.</i> 2017 May/Jun;40(3):245-254.</p> <p>Liu KL, Shih IL, Huang YC, Chen CH. Image of the Month: Abdominoscrotal Hydrocele. <i>Am J Gastroenterol.</i> 2016 Mar;111(3):312.</p> <p>Chang MC, Chen CH, Liang JD, Tien YW, Hsu C, Wong JM, Chang YT. Hepatitis B and C viruses are not risks for pancreatic adenocarcinoma. <i>World J Gastroenterol.</i> 2014 May 7;20(17):5060-5.</p> <p>Chen BB, Shih IL, Wu CH, Hsu C, Chen CH, Shih TT, Liu KL, Liang PC. Comparison of characteristics and transarterial chemoembolization outcomes in patients with unresectable hepatocellular carcinoma and different viral etiologies. <i>J Vasc Interv Radiol.</i> 2014 Mar;25(3):371-8.</p>			

中文姓名	魏國良	英文姓名	Kuo-Liang Wei	
國籍	台灣	性別	<input checked="" type="checkbox"/> 男 <input type="checkbox"/> 女	
主要學歷	台北醫學大學醫學系			
專長	胰臟疾病、一般胃腸疾病、ERCP 胰臟內視鏡攝影、 肝炎、肝癌			
現職	嘉義長庚醫院胃腸肝膽科 主治醫師			
經歷	台北長庚醫院內科部住院醫師 台北長庚醫院胃腸肝膽科主治醫師 嘉義長庚醫院胃腸肝膽科主任			
論文著作	<p>Lin MS, Chung CM, Lin WY, Wei KL, Wang J, Lee YY, Hu JH, Tung TH, Lin YS. Antiviral therapy reduces risk of haemorrhagic stroke in patients with HCV infection: a nationwide cohort study. Antivir Ther, 2017 May 4.</p> <p>Chang TS, Wei KL, Lu CK, Chen YH, Cheng YT, Tung SY, Wu CS, Chiang MK. Inhibition of CCAR1, a Coactivator of β-Catenin, Suppresses the Proliferation and Migration of Gastric Cancer Cells. Int J Mol Sci, 2017,18(2).</p> <p>Chang KC, Chen WM, Wei KL*. Endoscopic treatment of Bouverets syndrome in an extremely elderly patient with Holmium: YAG laser. Ann Saudi Med, 2016, 36(6):436-439.</p> <p>Chang TS, Wu YC, Tung SY, Wei KL, Hsieh YY, Huang HC, Chen WM, Shen CH, Lu CH, Wu CS, Tsai YH, Huang YH. Corrigendum: Alpha-Fetoprotein Measurement Benefits Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis. Am J Gastroenterol, 2016, 111(11):1668.</p> <p>Yen YH, Huang CM, Wei KL, Wang JH, Lu SN, Lee CM, Hung CH, Chen CH, Tseng PL, Chang KC, Tsai MC, Lin MT, Wu CK, Yang CH, Moi SH, Cho CL, Hu TH. MicroRNA-122 as a predictor of HBsAg seroclearance in hepatitis B and C dual infected patients treated with interferon and ribavirin. Sci Rep, 2016, 6:33816.</p> <p>Wu CS, Wei KL, Chou JL, Lu CK, Hsieh CC, Lin JM, Deng YF, Hsu WT, Wang HM, Leung CH, Ma DL, Li C, Chan MW. Aberrant JAK/STAT Signaling Suppresses TFF1 and TFF2 through Epigenetic Silencing of GATA6 in Gastric Cancer. Int J Mol Sci, 2016, 17(9).</p> <p>Wei KL, Chen FY, Lin CY, Gao GL, Kao WY, Yeh CH, Chen CR, Huang HC, Tsai WR, Jong KJ, Li WJ, Su JG. Activation of aryl hydrocarbon receptor reduces carbendazim-induced cell death. Toxicol Appl Pharmacol, 2016, 306:86-97.</p> <p>Chen WM, Wei KL, Chen YS, Chang PJ, Tung SY, Chang TS, Huang HC, Shen CH, Hsieh YY, Wu CS. Transpapillary biliary biopsy for malignant biliary strictures: comparison between cholangiocarcinoma and pancreatic cancer. World J Surg Oncol, 2016, 14:140.</p> <p>Chen WM, Shaw LH, Chang PJ, Tung SY, Chang TS, Shen CH, Hsieh YY, Wei KL. Hepatoprotective effect of resveratrol against ethanol-induced oxidative stress through induction of superoxide dismutase in vivo and in vitro. Exp Ther Med, 2016,11(4):1231-1238.</p> <p>Xu HW, Hsu YC, Chang CH, Wei KL, Lin CL. High FIB-4 index as an independent risk factor of prevalent chronic kidney disease in patients with nonalcoholic fatty liver disease. Hepatol Int, 2016,10(2):340-6.</p> <p>Chang TS, Wu YC, Tung SY, Wei KL, Hsieh YY, Huang HC, Chen WM, Shen CH, Lu CH, Wu CS, Tsai YH, Huang YH. Alpha-Fetoprotein Measurement Benefits Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis. Am J Gastroenterol, 2015, 110(6):836-44.</p> <p>Chen CH, Chen WM, Tung SY, Wu CS, Tong WL, Lee KF, Wei KL. Transpapillary biliary biopsy for malignant biliary strictures: comparison between cholangiocarcinoma and pancreatic cancer. World J Surg Oncol, 2015,13:174.</p>			

中文姓名	劉振驊	英文姓名	Chen-Hua Liu	
國籍	台灣	性別	<input checked="" type="checkbox"/> 男 <input type="checkbox"/> 女	
主要學歷	國立台灣大學醫學院醫學系學士 國立台灣大學醫學院臨床醫學研究所博士			
專長	一般內科學、腸胃學、肝炎病毒學			
現職	國立台灣大學附設醫院內科部主治醫師 國立台灣大學醫學院內科助理教授			
經歷	台大醫院內科部住院醫師 台大醫院雲林分院內科部主治醫師			
論文著作	<p>Liu CH, Chen YS, Wang SS, Liu CJ, Su TH, Yang HC, Hong CM, Chen PJ, Chen DS, Kao JH. Sofosbuvir-based interferon-free direct acting antiviral regimens for heart transplant recipients with chronic hepatitis C virus infection. Clin Infect Dis, 2017 Sep 4.</p> <p>Tseng TC, Liu CJ, Su TH, Yang WT, Chen CL, Yang HC, Wang CC, Kuo SF, Liu CH, Chen PJ, Chen DS, Kao JH. Fibrosis-4 Index Helps Identify HBV Carriers With the Lowest Risk of Hepatocellular Carcinoma. Am J Gastroenterol, 2017,112(10):1564-1574.</p> <p>Liu CH, Liu CJ, Su TH, Yang HC, Hong CM, Tseng TC, Chen PJ, Chen DS, Kao JH. Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan. J Gastroenterol Hepatol, 2017 Aug 1.</p> <p>Lee MH, Huang CF, Lai HC, Lin CY, Dai CY, Liu CJ, Wang JH, Huang JF, Su WP, Yang HC, Kee KM, Yeh ML, Chuang PH, Hsu SJ, Huang CI, Kao JT, Chen CC, Chen SH, Jeng WJ, Yang HI, Yuan Y, Lu SN, Sheen IS, Liu CH, Peng CY, Kao JH, Yu ML, Chuang WL, Chen CJ. Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients. Sci Rep, 2017, 7(1):3718.</p> <p>Liu CH, Liu CJ, Hong CM, Su TH, Yang HC, Chen KM, Huang YP, Yeh YM, Tien HL, Liu YC, Kao JH, Chen DS, Chen PJ. A noninvasive diagnosis of hepatic fibrosis by BioFibroScore® in chronic hepatitis C patients. J Gastroenterol Hepatol, 2017 May 26.</p> <p>Su TH, Shiau CW, Jao P, Yang NJ, Tai WT, Liu CJ, Tseng TC, Yang HC, Liu CH, Huang KW, Hu TC, Huang YJ, Wu YM, Chen LJ, Chen PJ, Chen DS, Chen KF, Kao JH. Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis. Sci Rep, 2017, 7(1):1728.</p> <p>Liu CH, Liu CJ, Su TH, Fang YJ, Yang HC, Chen PJ, Chen DS, Kao JH. Hepatitis B Virus Reactivation in Patients Receiving Interferon-Free Direct-Acting Antiviral Agents for Chronic Hepatitis C Virus Infection. Open Forum Infect Dis, 2017, 4(1):ofx028.</p> <p>Liu CH, Chen YS, Wang SS, Kao JH. Treatment of de novo hepatitis C virus-related fibrosing cholestatic hepatitis after orthotopic heart transplantation by ledipasvir and sofosbuvir. J Formos Med Assoc, 2017, 116(5):407-409.</p> <p>Kao JH, Ahn SH, Chien RN, Cho M, Chuang WL, Jeong SH, Liu CH, Paik SW. Urgency to treat patients with chronic hepatitis C in Asia. J Gastroenterol Hepatol, 2017, 32(5):966-974.</p> <p>Mah YH, Liu CH, Chen CL, Tseng TC, Liu CJ, Chen PJ, Chen DS, Kao JH. Prevalence and clinical implications of IL28B genotypes in Taiwanese patients with chronic hepatitis C. J Formos Med Assoc, 2016, 115(11):953-960.</p> <p>Yang WT, Wu LW, Tseng TC, Chen CL, Yang HC, Su TH, Wang CC, Kuo SF, Liu CH, Chen PJ, Chen DS, Liu CJ, Kao JH. Hepatitis B Surface Antigen Loss and Hepatocellular Carcinoma Development in Patients With Dual Hepatitis B and C Infection. Medicine (Baltimore), 2016, 95(10):e2995.</p> <p>Su TH, Liu CJ, Tseng TC, Chou SW, Liu CH, Yang HC, Wu SJ, Chen PJ, Chen DS, Chen CL, Kao JH. Hepatitis C viral infection increases the risk of lymphoid-neoplasms: A population-based cohort study. Hepatology, 2016, 63(3):721-30.</p>			